Clinical efficacy and residual renal function of Roxallistat combined with L-carnitine in maintenance hemodialysis with renal anemia
Objective:To analyze the clinical efficacy and residual renal function of Roxallistat combined with L-carnitine in the treatment of maintenance hemodialysis with renal anemia.Methods:80 patients with maintenance hemodialysis with renal anemia admitted to our hospital from June 2022 to June 2023 were selected and divided into control group(treated with Rosallistat capsule)and observation group(treated with Rosallistat capsule combined with L-carnitine)according to different treatments,with 40 cases in each group.After 8 w of treatment,anemia indexes,such as Red blood cell(RBC),Hemoglobin(Hb),Hematocrit(Hct)level,and renal function indexes,were detected by automatic blood analyzer.Including Blood urea nitrogen(BUN),Serum Creatinine(SCr),24h Urinary protein excretion rate(24hUPE)level.Enzyme-linked immunoassay was used to detect iron metabolism indexes:Serum Ferritin(SF),Transferrin saturation(TSAT),Serum transferrin receptor(STFR)levels;Diastolic and systolic blood pressure were measured by a sphygmomanometer.Results:The total effective rate of observation group(97.50%)was higher than that of control group(85.00%)(P<0.05).After 8 w of treatment,RBC,Hb,Hct,SF,TSAT,STAT levels and 24h urine volume were increased,BUN,SCr,24hUPE levels and blood pressure fluctuation were decreased in both groups.The observation group was more significant than the control group(P<0.05).The incidence of adverse reactions in observation group(7.50%)was lower than that in control group(15.00%),but there was no statistical difference(P>0.05).Conclusion:Roxallistat combined with L-carnitine maintenance hemodialysis with renal anemia can alleviate clinical symptoms,improve anemia and renal function related indexes,and the drug is safe and reliable.
RosalrestatL-carnitineMaintenance hemodialysisRenal anemiaClinical effectRenal function
万方数据
维普
